TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 58nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 62nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 720nMAssay Description:Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptorMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 780nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 4.20E+3nMAssay Description:Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptorMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 5.30E+3nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: <1.00E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 1.45E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataKi: 6.20E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 355nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.12E+3nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 7.97E+3nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 9.60E+3nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.14E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.62E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 3.27E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.05E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 5.20E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 5.53E+4nMAssay Description:Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptorMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 5.55E+4nMAssay Description:Inhibition of human washed platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.72E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.82E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 7.34E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 7.59E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 8.20E+4nMAssay Description:Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptorMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 9.13E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 9.70E+4nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.02E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.13E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.38E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.38E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of 125[I] Fibrinogen binding to isolated purified human fibrinogen receptorMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of canine platelet-rich plasma agregation induced by ADPMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human washed platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of thrombin-stimulated platelet aggregation in dogsMore data for this Ligand-Target Pair